The federal drug pricing program 340B helps hospitals and clinics in Virginia and across the nation care for underserved ...

The breadth of the proposal suggests that many organizations will need to reassess existing policies, contractual ...

The 340B Drug Pricing Program may be partly driving U.S. hospital consolidation and worsening affordability for patients, ...

Outpatient drug purchases under the 340B Drug Pricing Program crossed the $100 billion mark across 2025, a roughly 23% ...

A clear look at the 340B program: how hospitals generate revenue from drug discounts, why it has expanded, and the growing policy debate.

AHA responds to Information Collection Request about the Health Resources and Services Administration’s proposed 340B Rebate Model Program.

CMS would set 340B drug payment at ASP–33.4%, lowering Medicare and beneficiary drug outlays while redistributing equivalent ...

Even as they sparred on broader healthcare policy and funding topics fueling the ongoing government shutdown, senators of the Health, Education, Labor and Pensions Committee appear to agree that ...

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

The 340B fights of 2026 are being waged as disputes over fairness and intent. Underneath, they are disputes over data.

“When a program designed to deliver targeted assistance drives up system-wide costs, reform is no longer optional,” says health expert Sally Pipes. “It's necessary.” If a charity organization ...

Unexpected windfall or fragile safety net? Affluent communities or vulnerable poor? Welfare check or supplemental provider program? Making sense of the latest 340B program study published by the ...